Reproducibility of mRECIST criteria for assessment of HCC treated by anti-VEGFR therapy: Impact of the reader's experience
Hubert Beaumont [1], Sophie Egels [2], Nathalie Faye [1], Catherine Klifa [1], Antoine Iannessi [3], Eric Bonnard [3], Olivier Lucidarme [2] -Affiliations: [1] Median Technologies, Valbonne, France. [2] Hôpital La Pitié Salpétrière, Paris, France. [3] Centre Antoine Lacassagne, Nice, France.
Poster presented at the ESMO 2018 Congress, in Munich. Study was performed in collaboration with the French Hospital La Pitie-Salpetriere (AP-HP, France) and the Antoine Lacassagne Cancer Center (Nice, France).